In animal MS models, a new treatment cleared lesions
By MS Buddy ·
Summarized from Proceedings of the National Academy of Sciences of the United States of America, Nov 2025 · PubMed · DOI. AI-generated summary. Not medical advice.
Animal study · animal models of MS and primates
Research by Senta Kapnick, Christopher Jewell and 20 colleagues at the University of Maryland, College Park in the United States.
Did a treatment placed in lymph nodes clear MS-like nerve damage in animals?
Key Takeaway
In animal models of MS, a treatment placed in immune-system hubs cleared areas of nerve damage without weakening the response to a vaccine challenge.

What They Found
Researchers placed small, slow-release treatment deposits in immune-system hubs called lymph nodes. In animal models of MS, the treatment helped immune cells stop attacking the nerve covering. Areas of nerve damage disappeared after treatment. One treatment produced lasting improvement in these models. The animals still responded to a vaccine challenge.
Who Should Care and Why
This study used animal models of MS and also tested how well primates tolerated the treatment. The MS findings came from animal models, not people with MS. The treatment was placed in lymph nodes, where immune cells gather. Researchers found that it changed how immune cells responded to the nerve covering. Primates tolerated the treatment well, but the abstract does not describe testing its effects on MS in primates.
Important Considerations
You cannot tell from this study whether the treatment would help people with MS. You also cannot tell whether it would be safe for people. The abstract gives no number of animals studied.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Proceedings of the National Academy of Sciences of the United States of America by et al.. Reproduced from the PubMed record.
Development of tolerogenic, antigen-specific immunotherapies could overcome limitations of existing treatments for inflammatory autoimmune diseases by achieving potent, durable remission without impacting healthy immune surveillance. Here, we deliver diffusion-limited polymer depots to lymph nodes to locally guide T cell fates for the treatment of multiple sclerosis (MS), an autoimmune disease that occurs when the immune system mistakenly attacks myelin. In preclinical MS models, depots loaded with myelin self-antigen and tolerizing cues mediate localized retention of activated CD4 T cells, promote myelin-specific regulatory T cells, and reshape inflammation in the central nervous system (CNS) to eliminate lesions. Selective disease reversal is achieved with a single treatment that induces long-lasting remission without hindering healthy responses to vaccine challenge with foreign antigen. Furthermore, depots offer favorable chemistry and manufacturing control features and are well tolerated in non-human primates. This work supports a clinically feasible concept for inducing safe, effective, antigen-specific tolerance without systemic or repeated dosing.
Categories
Explore more research
Related MS research

11/16/2026
A planned study will use detailed brain scans and blood tests to explore why relapsing-remitting MS
Read More
11/15/2026
In tissue from mice with an MS-like disease, a lab drug reduced excess chemical release from nerve e
Read More
11/13/2026
A review compares MS with harmful drug reactions and proposes ways to test how immune genes, lasting
Read More
11/13/2026
This review examines how vitamin D and vitamin A signals shape immune activity in MS and other disea
Read More
11/12/2026
In mice with an MS-like disease, a lab-made protein improved movement and thinking. Researchers also
Read More
11/12/2026
A review proposes how the Epstein-Barr virus might contribute to MS. The model brings earlier ideas
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
